BioXcel Therapeutics, Inc. insiders have only been selling lately: four insiders unloaded about $43,000 of stock over 12 months, with no open-market purchases.
That's worth context: executives sell for plenty of routine reasons, from scheduled trading plans to tax bills. Buying is the rarer, more telling signal.
No open-market insider buying or selling in the last full quarter. Insiders bought in 0 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | Yocca Frank | Executive Officer | Sell | 6,845 | $1.09 | $7K | SEC |
| May 22, 2026 | Rodriguez Javier | Officer | Sell | 6,560 | $1.08 | $7K | SEC |
| May 22, 2026 | Steinhart Richard I | CFO | Sell | 6,845 | $1.09 | $7K | SEC |
| May 22, 2026 | Mehta Vimal | CEO | Sell | 19,419 | $1.09 | $21K | SEC |
| Dec 17, 2024 | O'Neill Vincent | Officer | Sell | 165 | $0.35 | $58 | SEC |
| Dec 17, 2024 | Mehta Vimal | CEO | Sell | 983 | $0.36 | $354 | SEC |
| Dec 17, 2024 | Mehta Vimal | CEO | Sell | 2,134 | $0.36 | $768 | SEC |
| Dec 17, 2024 | Steinhart Richard I | CFO | Sell | 205 | $0.36 | $74 | SEC |
| Dec 17, 2024 | Steinhart Richard I | CFO | Sell | 372 | $0.36 | $134 | SEC |
| Dec 17, 2024 | Yocca Frank | Executive Officer | Sell | 205 | $0.36 | $74 | SEC |
| Dec 17, 2024 | Yocca Frank | Executive Officer | Sell | 225 | $0.35 | $79 | SEC |
| Oct 3, 2024 | Rodriguez Javier | Officer | Sell | 6,863 | $0.55 | $4K | SEC |
| Oct 3, 2024 | Yocca Frank | Executive Officer | Sell | 7,175 | $0.55 | $4K | SEC |
| Oct 3, 2024 | Steinhart Richard I | CFO | Sell | 7,175 | $0.55 | $4K | SEC |
| Oct 3, 2024 | O'Neill Vincent | Officer | Sell | 5,556 | $0.55 | $3K | SEC |
In the last 12 months BioXcel Therapeutics, Inc. insiders made open-market purchases worth about $0 and sales worth about $43,000. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in BTAI was filed on 2026-05-22.
No congressional trades in BTAI were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).